Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02789657
Title Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors William Sikov MD
Indications

Her2-receptor positive breast cancer

Therapies

Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab

Cyclophosphamide + Doxorubicin

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.